Added to YB: 2026-01-15
Pitch date: 2026-01-13
BNTX [neutral]
BioNTech SE
-0.14%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
Market Cap
$22.0B
Pitch Price
$109.27
Price Target
N/A
Dividend
N/A
EV/EBITDA
-18.17
P/E
-36.70
EV/Sales
2.43
Sector
Biotechnology
Category
growth
BioNTech (BNTX Germany): a quiet revenue bridge year ahead of a defining oncology inflection
BNTX (update): 2026 shaping up as defining year w/ multiple late-stage oncology readouts across breast, lung, colorectal cancers. Covid revenue declining but $17B cash provides flexibility. No oncology revenue expected 2026, emphasis on clinical proof points. Success could shift narrative from optionality to execution as multi-asset oncology player.
Read full article (2 min)